ClinicalTrials.gg
CompletedNCT01040286Updated Jul 7, 2010

The Efficacy and Safety of Flurbiprofen Chip Versus Chlorhexidine Chip (Periochip®) in Therapy of Adult Chronic Periodontitis

A Phase 2 interventional study of Flurbiprofen and Chlorhexidine in Periodontitis, sponsored by Dexcel Pharma Technologies Ltd.. Completed at 1 site in Israel. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2010-07-07.

Sponsored by Dexcel Pharma Technologies Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies in Periodontitis with a site in Israel — none open to participants now, none under way, none of them phase 3. Periodontitis · Israel.

Started
2009
with 1 other
Phase 2
2 of 10
none open now
Registered
5th of 10
by date
Lead sponsor
2 of 10
Dexcel Pharma Technologies Ltd.

Among the 10 studies in Periodontitis with a site in Israel, this one is one of 2 that started in 2009, is one of 2 in phase 2, and was the 5th registered.

Periodontitis

1,235 studies on the registry are indexed under Periodontitis; 298 are open to participants now.

Browse Periodontitis studies →

Open to participants now

None of the 10 studies in Periodontitis with a site in Israel is open now. The open studies under Periodontitis, anywhere →

Who these studies take

Of the 160 Periodontitis studies recruiting now, 79 (49%) set no upper age limit and 60 (38%) stop at 75 or younger; 12 take children under 18; 77 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies in Periodontitis with a site in Israel as a file.
02

Study summary

The purpose of the study is to assess efficacy and safety of Flurbiprofen Chip versus Chlorhexidine chip (Periochip®) in therapy of adult chronic periodontitis.

03

Conditions studied

  • Periodontitis

Browse trials for

Keywords

  • Subjects, age>21, with Chronic periodontal disease on natural teeth characterized by the presence of at least 2 teeth with periodontal
  • pockets of 5-9 mm in depth demonstrating bleeding on probing without involving the
  • apex of the tooth and confirmed by dental X-ray.
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed and dated form
  2. Good general health
  3. Male or female subjects aged >21 years old
  4. Availability for the 9 week duration of the study
  5. Chronic periodontal disease on natural teeth characterized by the presence of at least 2 teeth with periodontal pockets of 5-9 mm in depth (potential target teeth) demonstrating bleeding on probing without involving the apex of the tooth and confirmed by dental X-ray.
  6. Females of must be non-pregnant and non-lactating at entry and agree to use an adequate method (Oral or parenteral hormonal ; Intrauterine device; barrier and spermicide) of birth control during the study.

Exclusion criteria

Exclusion Criteria:

  1. An existing aggressive periodontitis.
  2. Presence of oral local mechanical factors that could (in the opinion of the investigator) influence the outcome of the study.
  3. Presence of orthodontic appliances, or any removable appliances, that impinge on the tissues being assessed.
  4. Soft or hard tissue tumours of the oral cavity.
  5. Presence of dental implant adjacent to target tooth.
  6. Presence of more than 2 adjacent periodontal pockets on the same potential target tooth.
  7. Periodontal pockets of more than 9 mm in depth, and/or with class 2 or 3 furcation involvement, on the potential target tooth.
  8. Systemic antibiotic therapy or periodontal/mechanical/local delivery therapy within 6 weeks prior to study entry and throughout the study duration.
  9. History of allergy to chlorhexidine, flurbiprofen or to other non-steroidal anti-inflammatory drugs (NSAIDs).
  10. Subjects taking Phenytoin, calcium channel blockers drugs (CCBs) and/or cyclosporine, which might influence the pattern of tissue response.
  11. Subjects treated with non-steroidal anti-inflammatory drugs (NSAIDs) within 14 days prior to entry into the study and throughout the study duration.
  12. Presence of the following conditions: Type 1 diabetes, major recurrent aphtae, stomatitis, abscesses and related oral pathologies.
  13. The presence of any medical or psychiatric condition that in the opinion of the investigator could affect the successful participation of the subject in the study.
  14. Subject participates in any other clinical study 30 days prior to the start of the study and throughout the study duration.
  15. Subject uses chlorhexidine oral rinses/ mouthwashes on a regular basis.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)

Study arms

  • Experimental
    Flurbiprofen Chip

    Drug: Flurbiprofen

  • Active comparator
    Chlorhexidine chip

    Drug: Chlorhexidine

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Probing Pocket Depth reduction

    Time frame: 8 weeks

Secondary outcomes

  1. clinical attachment levels (CAL) and bleeding on probing (BOP)

    Time frame: 8 weeks

07

Study locations

1 site
  • Department of Periodontology, School of Graduate Dentistry, Rambam Health Care Center
    Haifa, 9602, Israel
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2009 and a completion of Jun 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 27, 2009
First posted
Dec 29, 2009
Start
Aug 2009
CompletionActual
Jun 2010
Last update
Jul 7, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01040286
Lead sponsor
Dexcel Pharma Technologies Ltd.
First posted
Dec 29, 2009
Start date
Aug 2009
Completion
Jun 2010
Last update
Jul 7, 2010

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Flurbiprofen

Start the discussion